Furthermore, we find that IRF4 over-expression decreases the levels of both NFATc1 and NFATc2 in EBV-positive Burkitt lymphoma cells and inhibits lytic EBV reactivation in response to BCR activation. This evidence concerns the gene IRF4 and Burkitt lymphoma.